The estimated Net Worth of Nessan Bermingham is at least $16.3 million dollars as of 6 December 2017. Mr Bermingham owns over 336,783 units of Intellia Therapeutics Inc stock worth over $9,274,980 and over the last 9 years he sold NTLA stock worth over $6,998,351.
Mr has made over 1 trades of the Intellia Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 336,783 units of NTLA stock worth $6,998,351 on 6 December 2017.
The largest trade he's ever made was selling 336,783 units of Intellia Therapeutics Inc stock on 6 December 2017 worth over $6,998,351. On average, Mr trades about 67,357 units every 0 days since 2016. As of 6 December 2017 he still owns at least 458,250 units of Intellia Therapeutics Inc stock.
You can see the complete history of Mr Bermingham stock trades at the bottom of the page.
Nessan Bermingham Ph.D. is the Founder & Member of Scientific Advisor Board at Intellia Therapeutics Inc.
Mr D is 48, he's been the Founder & Member of Scientific Advisor Board of Intellia Therapeutics Inc since . There are 17 older and 2 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Nessan's mailing address filed with the SEC is 40 Erie St, Cambridge, MA 02139, USA.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela et Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: